|
|||||
|
|
| 迁移侵袭抑制蛋白在肿瘤发生发展中的作用及其临床意义 | |
| 引用本文： | 王超,孙燕. 迁移侵袭抑制蛋白在肿瘤发生发展中的作用及其临床意义[J]. 中国肿瘤临床, 2018, 45(3): 146-151. DOI: 10.3969/j.issn.1000-8179.2018.03.307 |
| 作者姓名： | 王超 孙燕 |
| 作者单位： | 天津医科大学肿瘤医院病理科，国家肿瘤临床医学研究中心，天津市肿瘤防治重点实验室，天津市恶性肿瘤临床医学研究中心（天津市300060） |
| 基金项目： | 国家自然科学基金面上项目81472263 |
| 摘 要： | 迁移侵袭抑制蛋白（migration and invasion inhibitory protein，MIIP）能够与胰岛素样生长因子结合蛋白2（insulin-like growth factor binding protein 2，IGFBP2）、组蛋白去乙酰化酶6（histone deacetylase 6，HDAC6）、p21活化激酶1、表皮生长因子受体、细胞分裂周期20（cell division cycle 20，cdc20）、拓扑异构酶等相互作用，抑制细胞增殖和迁移侵袭，进而抑制多种肿瘤的发生发展。最近的研究显示，MIIP还与病毒感染、细胞免疫有关。鉴于MIIP的作用涉及到多条肿瘤相关的信号通路及肿瘤治疗靶点，MIIP逐渐成为研究的热点。本文主要围绕MIIP的分子特征、功能和在多种肿瘤中的临床意义及作用机制进行综述。 |
| 关 键 词： | 迁移侵袭抑制蛋白 抑癌基因 有丝分裂 细胞迁移 基因组不稳定 |
| 收稿时间： | 2017-11-23 |
The role and clinical significance of migration and invasion inhibitory protein in the development and progression of tumors |
|
| Affiliation: | Department of Pathology, Tianjin Medical University Cancer Institute and Hospital; National Clinical Research Center for Cancer; Tianjin Key Laboratory of Cancer Prevention and Therapy; Tianjin's Clinical Research Center for Cancer, Tianjin 300060, China |
| Abstract: | Migration and invasion inhibitory protein (MIIP) inhibits cell proliferation, migration, and invasion, impeding tumorigenesis and tumor progression, by interacting with insulin-like growth factor binding protein 2 (IGFBP2), histone deacetylase 6 (HDAC6), p21 activated kinase 1 (PAK1), epidermal growth factor receptor (EGFR), cell division cycle 20 (CDC20), and topoisomerase. Recent studies revealed potential roles of MIIP in viral infection and cellular immunity. MIIP has become a research hotspot owing to its involvement in multiple signaling pathways and as a potential therapeutic target for tumors. This review summarizes the characteristics, functions, clinical significance, and possible pathogenic mechanisms of MIIP in multiple carcinomas. |
| Keywords: | |
| 点击此处可从《中国肿瘤临床》浏览原始摘要信息 | |
| 点击此处可从《中国肿瘤临床》下载免费的PDF全文 | |